Pub. Date : 2010
PMID : 23762931
5 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | Development of a Selective, Allosteric PLD2 Inhibitor A diversity-oriented synthesis approach of the neuroleptic drug halopemide, reported to be a phospholipase D2 (PLD2) inhibitor (but later shown to be a dual PLD1/2 inhibitor) afforded ML298 (CID 53393915), a potent, >53-fold PLD2 selective allosteric inhibitor (cellular PLD1, IC50 >20,000 nM, cellular PLD2, IC50 = 355 nM). | halopemide | phospholipase D2 | Homo sapiens |
| 2 | Development of a Selective, Allosteric PLD2 Inhibitor A diversity-oriented synthesis approach of the neuroleptic drug halopemide, reported to be a phospholipase D2 (PLD2) inhibitor (but later shown to be a dual PLD1/2 inhibitor) afforded ML298 (CID 53393915), a potent, >53-fold PLD2 selective allosteric inhibitor (cellular PLD1, IC50 >20,000 nM, cellular PLD2, IC50 = 355 nM). | halopemide | phospholipase D2 | Homo sapiens |
| 3 | Development of a Selective, Allosteric PLD2 Inhibitor A diversity-oriented synthesis approach of the neuroleptic drug halopemide, reported to be a phospholipase D2 (PLD2) inhibitor (but later shown to be a dual PLD1/2 inhibitor) afforded ML298 (CID 53393915), a potent, >53-fold PLD2 selective allosteric inhibitor (cellular PLD1, IC50 >20,000 nM, cellular PLD2, IC50 = 355 nM). | halopemide | phospholipase D2 | Homo sapiens |
| 4 | Development of a Selective, Allosteric PLD2 Inhibitor A diversity-oriented synthesis approach of the neuroleptic drug halopemide, reported to be a phospholipase D2 (PLD2) inhibitor (but later shown to be a dual PLD1/2 inhibitor) afforded ML298 (CID 53393915), a potent, >53-fold PLD2 selective allosteric inhibitor (cellular PLD1, IC50 >20,000 nM, cellular PLD2, IC50 = 355 nM). | halopemide | phospholipase D2 | Homo sapiens |
| 5 | Development of a Selective, Allosteric PLD2 Inhibitor A diversity-oriented synthesis approach of the neuroleptic drug halopemide, reported to be a phospholipase D2 (PLD2) inhibitor (but later shown to be a dual PLD1/2 inhibitor) afforded ML298 (CID 53393915), a potent, >53-fold PLD2 selective allosteric inhibitor (cellular PLD1, IC50 >20,000 nM, cellular PLD2, IC50 = 355 nM). | halopemide | phospholipase D2 | Homo sapiens |